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Nau F Jr, Miller J, Saravia J, Ahlert T, Yu B, Happel KI,
Cormier SA, Nichols CD. Serotonin 5-HT2 receptor activation pre-
vents allergic asthma in a mouse model. Am J Physiol Lung Cell Mol
Physiol 308: L191–L198, 2015. First published November 21, 2014;
doi:10.1152/ajplung.00138.2013.—Asthma is an inflammatory dis-
ease of the lung characterized by airways hyper-responsiveness
(AHR), inflammation, and mucus hyperproduction. Current main-
stream therapies include bronchodilators that relieve bronchoconstric-
tion and inhaled glucocorticoids to reduce inflammation. The small
molecule hormone and neurotransmitter serotonin has long been
known to be involved in inflammatory processes; however, its precise
role in asthma is unknown. We have previously established that
activation of serotonin 5-hydroxytryptamine (5-HT)2A receptors has
potent anti-inflammatory activity in primary cultures of vascular
tissues and in the whole animal in vasculature and gut tissues. The
5-HT2A receptor agonist, (R)-2,5-dimethoxy-4-iodoamphetamine
[(R)-DOI] is especially potent. In this work, we have examined the
effect of (R)-DOI in an established mouse model of allergic
asthma. In the ovalbumin mouse model of allergic inflammation,
we demonstrate that inhalation of (R)-DOI prevents the develop-
ment of many key features of allergic asthma, including AHR,
mucus hyperproduction, airways inflammation, and pulmonary
eosinophil recruitment. Our results highlight a likely role of the
5-HT2 receptors in allergic airways disease and suggest that 5-HT2
receptor agonists may represent an effective and novel small
molecule-based therapy for asthma.
serotonin; inflammation; 5-HT2 receptor; 5-HT2A receptor; asthma;
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SEROTONIN [5-hydroxytryptophan (5-HT)] is a ubiquitous,
small hormone molecule, present in nearly all eukaryotes,
that mediates a wide spectrum of physiological processes. In
mammals, it exerts its action through 14 different receptor
subtypes that comprise seven distinct families (5-HT1–7)
(34). All but one family, the ligand-gated 5-HT3 receptor ion
channel, are G-protein-coupled receptors (34). The 5-HT2A
receptor is known primarily for its role in mediating com-
plex cognitive behaviors within the central nervous system
and for mediating physiological processes, such as vasocon-
striction, in the periphery (32, 34). Interestingly, the 5-HT2A
receptor is the primary target of classic hallucinogenic
drugs, such as lysergic acid diethylamide, which produces
intoxicating effects. Although 5-HT2A receptor mRNA is
expressed at higher levels in immune-related tissues, such as
spleen, thymus, and peripheral-circulating lymphocytes,
compared with other serotonin receptor subtypes (i.e.,
5-HT1A, 5-HT1D, 5-HT2C, 5-HT4, 5-HT5A, and 5-HT5B)
(42), its precise role in inflammatory processes is not well
defined. With regard to the potential role of serotonin in
asthma, 5-HT2A receptors are functionally expressed in
activated CD4 T cells, alveolar macrophages, eosinophils,
and lung epithelial and smooth muscle cells (8, 20, 21, 23,
30). In fact, migration of eosinophils in allergic asthma has
been shown recently to be dependent on 5-HT2A receptor
activation (21), and 5-HT2 receptors have been implicated in
platelet function relevant to allergic asthma (13).
We reported recently that 5-HT2A receptor agonists potently
inhibit inflammation in vitro (53). The anti-inflammatory ef-
fects of one particular 5-HT2A receptor agonist, (R)-2,5-dime-
thoxy-4-iodoamphetamine [(R)-DOI], is extremely potent,
with an EC50 of 15 pM. Through activation of the 5-HT2A
receptor, (R)-DOI blocks the expression and activation of
proinflammatory markers, including expression of chemokines
[e.g., monocyte chemotactic protein-1 (MCP-1)], cellular ad-
hesion molecules (ICAM1 and VCAM1), cytokines (e.g., IL-6),
nitric oxide synthase, and activation/nuclear translocation of
NF-B, in a variety of cell types, including primary aortic
smooth muscle cells (53). We have translated these in vitro
findings to a whole animal mouse model of inflammation by
demonstrating that (R)-DOI, also through 5-HT2A receptor
activation, has potent anti-inflammatory effects when admin-
istered before systemically administered TNF-. These effects
are most pronounced in the vasculature and the gut, where
preadministration of (R)-DOI blocks TNF--induced increases
in the proinflammatory gene and protein expression, including
circulating IL-6 (33).
In an effort to extend our findings to the potential use of
(R)-DOI as a therapeutic in inflammatory airways disease,
herein, we examine the ability of (R)-DOI to block the key
features of allergic asthma in the well-established mouse model
of ovalbumin (OVA)-induced allergic asthma. In this model,
mice are sensitized and challenged with inhaled chicken OVA
peptide to induce a phenotype resembling human asthma,
including airways hyper-responsiveness (AHR) in response to
methacholine (MeCh), mucus hyperproduction, and pulmonary
inflammation characterized by eosinophilia (5). We show here
that inhaled (R)-DOI blocks AHR, recruitment of eosinophils
to the lung, mucus hyperproduction, and inflammatory airway
remodeling. We speculate that 5-HT2 receptor agonism may
represent a novel therapeutic strategy for asthma.
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MATERIALS AND METHODS
Drugs and reagents. (R)-DOI was generously provided by Dr.
David E. Nichols (Purdue University, West Lafayette, IN) and was
dissolved in sterile physiological saline before use. OVA and MeCh
were purchased from Sigma-Aldrich (St. Louis, MO).
Animals. For the inhalation/asthma experiments, specific pathogen-
free, wild-type BALB/c mice were purchased from Harlan Laborato-
ries (Indianapolis, IN). Mice were maintained in the animal care
facility at the Louisiana State University Health Sciences Center (New
Orleans, LA) in ventilated cages, housed in a pathogen-free animal
facility with free access to food and water. Animal protocols were
prepared in accordance with the Guide for the Care and Use of
Laboratory Animals and approved by the Institutional Animal Care
and Use Committee at Louisiana State University Health Sciences
Center.
Induction of allergic inflammatory airways disease, i.e., the OVA
mouse model of asthma. Mice (male; 6–8 wk old) were sensitized and
challenged with chicken OVA Grade V (Sigma-Aldrich), as described
previously (4). Briefly, mice were sensitized by an intraperitoneal
injection (100 l) of 20 g OVA, emulsified in 2 ml Imject Alum
[Al(OH)3/Mg(OH)2; Pierce, Rockford, IL] on days 0 and 14. Mice
were subsequently challenged with an OVA aerosol, generated using
an ultrasonic nebulizer (Pari Proneb nebulizer, Midlothian, WA) with
a 1% (wt/vol) OVA solution in saline for 20 min on days 24–26.
Thirty minutes before each OVA challenge, each mouse was treated
with one of two different concentrations of (R)-DOI (nose-only
inhalation of 0.01 or 1.0 mg/kg) or vehicle control using an ultrasonic
nebulizer (Aerogen, Galway, Ireland).
Measurement of airway inflammation, pulmonary mechanics, and
BALF cellularity. Pulmonary function testing, bronchoalveolar lavage
(BAL), and tissue harvests were performed on day 28 (when mice
were 10–12 wk of age). For the forced oscillation method, pulmonary
resistance was measured as described previously (11). In brief, anes-
thetized animals were mechanically ventilated with a tidal volume of
10 ml/kg and a frequency of 2.5 Hz using a computer-controlled
piston ventilator (flexiVent; SCIREQ, Montreal, Canada). Bronchial
tone was determined in response to increasing concentrations of the
aerosolized bronchoconstrictor MeCh (at 0, 6.25, 12.5, 25, and 50
mg/ml in isotonic saline). The single compartment model was used to
calculate airway resistance values, and peak values obtained after each
MeCh challenge were plotted (17). On protocol day 28, BAL fluid
(BALF) was harvested after pulmonary-function testing and analyzed
for cellularity, as described previously (3). Differential cell counts
were performed by two blinded observers using standard morpholog-
ical criteria to classify individual leukocyte populations. All mice
from each group were used for these analyses, and 200 cells were
counted per animal. For the whole-body method, AHR to MeCh (0,
3.125, 6.25, 12.5, 25, 50, and 100 mg/ml in isotonic saline) was
measured using whole-body plethysmography (Buxco Electronics,
Troy, NY, and EMKA Technologies, Falls Church, VA) and per-
formed as described previously (51). Mice were exposed to aerosol-
ized MeCh for 1 min at each dose, and peak enhanced pause (PenH)
response was recorded for 3 min. The maximum PenH was averaged
for each dose, and data were plotted as percent change from vehicle
controls.
Lung histopathology. Lungs were isolated and prepared as de-
scribed previously (52). Sections (4 m) were cut from paraffin-
embedded lungs and stained with periodic acid-Schiff staining to
visualize mucus and imaged as described previously (52). Adjacent
sections were stained with hematoxylin and eosin to visualize airway
morphology and cellular inflammation.
Measurement of total protein in BALF. Total protein was measured
from BALF, isolated on day 28, using the Thermo Scientific Pierce
bicinchoninic acid (BCA) protein assay kit (#23228), following the
manufacturer’s directions.
Measurement of total IgE and OVA-specific IgE. Whole blood was
taken via cardiac puncture by a 23-gauge needle on protocol day 28.
Whole blood was placed into plasma separator tubes coated in lithium
heparin (Becton Dickinson, Franklin Lakes, NJ). Plasma was isolated
from whole blood following the manufacturer’s protocols. Total
mouse IgE in the isolated plasma was determined using the ELISA
MAX Deluxe kit (Cat. No. 432404) and OVA-specific IgE was
determined using LEGEND MAX Mouse OVA Specific IgE ELISA
Kit (Cat. No. 439807), purchased from BioLegend (San Diego, CA).
Cytokine and chemokine analysis by qRT-PCR. Lungs were har-
vested 48 h after the final OVA exposure, and expression levels of
cytokines were determined using reverse transcription and quantita-
tive real-time PCR (qRT-PCR). For all lung tissues, RNA was
extracted with TRIzol reagent, purchased from Life Technologies
(Carlsbad, CA), following the manufacturer’s instructions. RNA was
processed into first-strand cDNA using the ImProm-II cDNA synthe-
sis kit (Promega, Madison, WI), following the manufacturer’s instruc-
tions. The input cDNA for each reaction was 500 ng total RNA.
Cytokine and chemokine mRNA expression, examined by probe-
based qRT-PCR, included the following: Il-4, Il-5, Il-6, Il-10, Il-13,
Tnf, Mcp-1, and granulocyte macrophage colony-stimulating factor
(Gm-csf). Primers were designed to be compatible with the Universal
ProbeLibrary system using the Universal ProbeLibrary Assay Design
Center (Roche Diagnostics, Indianapolis, IN) and synthesized by
Integrated DNA Technologies (Coralville, IA). Primer sequences used
in this study are as listed: Il-4 forward 5=-catcggcattttgaacgag-3= and
reverse 5=-cgagctcactctctgtggtg-3=; Il-5 forward 5=-acattgaccgccaaaaa-
gag-3= and reverse 5=-caccatggagcagctcag-3=; Il-6 forward 5=-
tctaattcatatcttcaaccaagagg-3= and reverse 5=-tggtccttagccactccttc-3=; Il-10
forward 5=-cagagccacatgctcctaga-3= and reverse 5=-tgtccagctggtcctttgtt-
3=; Il-13 forward 5=-cctctgacccttaaggagcttat-3= and reverse 5=-
cgttgcacaggggagtct-3=; Tnf forward 5=-tcttctcattcctgcttgtgg-3= and re-
verse 5=-ggtctgggccatagaactga-3=; Mcp-1 forward 5=-tcactgaagc-
cagctctctct-3= and reverse 5=-gatcatcttgctggtgaatgagt-3=; Gm-csf forward
5=-gcatgtagaggccatcaaaga-3= and reverse 5=-cgggtctgcacacatgtta-3=.
Probes used were from the Universal ProbeLibrary (Roche Diagnostics,
Indianapolis, IN) and are listed with the following universal probe
numbers: U2, U97, U78, U41, U17, U49, U22, and U79 for Il-4, Il-5, Il-6,
Il-10, Il-13, Tnf, Mcp-1, and Gm-csf, respectively. Quantification of
gene expression (see Fig. 6) was performed on a Roche LightCycler 480
Instrument II LC (Roche Diagnostics). Gene-expression levels were
calculated using the comparative threshold cycle method and normalized
to internal Gapdh expression, as determined using the Mouse GAPD
Gene Assay (Cat. no. 05046211001; Roche Diagnostics) in multiplex
format.
Statistics. All statistical analysis was performed using GraphPad
Prism (GraphPad Software, La Jolla, CA). See figure legends for
specific data.
RESULTS
Pulmonary administration of (R)-DOI is effective in prevent-
ing AHR in a mouse model of allergic asthma. Following OVA
sensitization and challenge, we measured airways resistance by
two different methods in separate groups of mice. For the first
method, we used the forced oscillation technique and in the
second method, whole-body plethysmography in awake, freely
moving mice. As expected, mice receiving only OVA develop
significant AHR in both methods (Fig. 1). Mice pretreated with
inhaled (R)-DOI at 0.01 (Fig. 1, A and B) or 1.0 mg/kg (Fig. 1,
A and C), before OVA challenge, display airways responsive-
ness not significantly different from naïve, as measured by
either method.
(R)-DOI prevents pulmonary inflammation and mucus
hyperproduction. Histopathological analysis of lung sections
from the different treatment groups demonstrated that as ex-
L192 5-HT2 ACTIVATION PREVENTS ASTHMA
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00138.2013 • www.ajplung.org
Downloaded from journals.physiology.org/journal/ajplung at LSU Louisiana State Univ (130.039.060.163) on September 24, 2021.
pected, OVA mice develop significant pulmonary inflamma-
tion and mucus. Animals treated with (R)-DOI (1.0 mg/kg)
before OVA exposure exhibit very little peribronchial inflam-
mation or mucus. Mice treated with two orders of magnitude
less (R)-DOI (0.01 mg/kg) demonstrate significantly reduced
inflammation and mucus production compared with the OVA-
only-exposed lungs (Figs. 2 and 3).
(R)-DOI reduces pulmonary inflammation and BALF
eosinophilia. Pulmonary inflammation is a common feature of
asthma and is partly responsible for increased AHR (15). To
associate (R)-DOI treatment and decreased AHR, as well as
normal-appearing histological results with lack of inflamma-
tion, we performed cell-differential counts on BALF cell pop-
ulations for each mouse in each group. As expected, OVA
induced a significant increase in the total number of cells
recovered in the BALF compared with naïve and (R)-DOI-
treated animals. A large fraction of the BALF cellularity was
due to elevated numbers of eosinophils (Fig. 4). Total BALF
cell numbers and eosinophil numbers for naïve, 0.01 mg/kg
DOI  OVA, and 1.0 mg/kg DOI  OVA were significantly
lower than the OVA-only mice (Fig. 4). Although the eosino-
phil numbers for the (R)-DOI-treated mice were greater than
Fig. 1. (R)-2,5-Dimethoxy-4-iodoamphetamine [(R)-DOI] prevents the development of airways hyperresponsiveness (AHR). A: in forced oscillation-resistance
measurements (flexiVent; SCIREQ), naïve mice and those treated nose only with 0.01 and 1.0 mg/kg (R)-DOI during the sensitization process exhibited
significantly different resistances from the ovalbumin (OVA)-only-treated group at 50 mg/ml methacholine (MeCh) and were not significantly different from
naïve, saline-treated mice [resistance  average of the fractional difference (	) of the value measured vs. the individual baseline values]. B and C: results from
whole-body plethysmography experiments in awake, freely moving mice are consistent with the forced oscillation results: pretreatment with (B) 0.01 mg/kg
(R)-DOI nose only and (C) 1.0 mg/kg (R)-DOI nose only significantly reduced the development of airways resistance. In all figure panels, DOI represents (R)-DOI
at the indicated dose. *P 
 0.05 OVA vs. Naïve, #P 
 0.05 OVA vs. (R)-DOI (1.0 mg/kg)  OVA, and P 
 0.05 OVA vs. (R)-DOI (0.01 mg/kg)  OVA;
n  5–9 animals/treatment group; error bars represent  SE; 2-way ANOVA with Bonferroni post hoc test. Peak enhanced pause maximum (PenH Max) values
represent baseline-normalized values.
Fig. 2. OVA-induced lung inflammation and mucus hyperproduction are inhibited by nose-only (R)-DOI. Representative sections of airways (4 m) stained with
the periodic acid-Schiff (PAS) technique are shown in this figure to highlight mucus (bright pink color). Saline-treated animals have normal airway morphology
and no mucus or inflammation (A and E). OVA-alone-treated animals have thickened airways with a significant amount of mucus present (B), as well as
peribronchial inflammation (F; arrows indicate inflammatory cells). Animals pretreated with (R)-DOI (1.0 mg/kg and 0.01 mg/kg nose only) demonstrate normal
airway morphology, with little to no detectable mucus or inflammation (C and G and D and H, respectively). A–D, 40 objective; E–H, 10 objective.
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those of naïve mice, they were not significantly different. There
is a trend for a decrease in the neutrophil numbers in (R)-DOI-
treated mice compared with OVA-treated mice; however, the
difference was not significant.
(R)-DOI does not alter lung leak or plasma IgE levels.
Increased protein content of the BALF is a hallmark of asthma
and the OVA model (46). Analysis of BALF total protein by BCA
assay from different treatment groups revealed a significant in-
crease between naïve and OVA groups but showed no difference
between mice treated with (R)-DOI  OVA and those animals
that were treated with OVA only (Fig. 5). The OVA model
characteristically produces increased serum levels of IgE and
OVA-specific IgE (19, 28, 56); therefore, we tested the effects of
(R)-DOI on total IgE and OVA-specific IgE. In both cases, we
measured a significant increase between naïve and OVA-treated
groups. (R)-DOI treatment, however, had no effect on either total
IgE or OVA-specific IgE as induced by OVA (Fig. 5).
(R)-DOI suppresses expression of genes involved in the T
cell and innate-immune cell response. A panel of cytokines and
chemokines typically involved in asthma and the OVA model
(Il-4, Il-5, Il-6, Il-10, Il-13, Tnf, Mcp-1, and Gm-csf) was
examined in the lungs by qRT-PCR (6, 10, 17, 29, 36, 45, 49).
There were, as anticipated, significant increases in mRNA for
Il-4, Il-5, Il-10, Il-13, Mcp-1, and Gm-csf with OVA treatment
compared with naïve mice. There was a trend that did not reach
significance for Il-6 and Tnf expression. (R)-DOI had no
effect on the increased expression levels of OVA-induced Il-4
or Il-10. Interestingly, (R)-DOI treatment significantly repressed
the OVA-induced increases in mRNA expression for Mcp-1,
Il-13, and Il-5 and completely blocked the increase in Gm-csf (Fig.
5). Although Il-6 expression was not up-regulated significantly in
the OVA group compared with vehicle control, (R)-DOI did
significantly reduce Il-6 expression levels in OVA-treated mice,
as expected from our previous studies in different inflammatory
models (Fig. 6).
DISCUSSION
To determine if serotonin 5-HT2 receptor activation with
(R)-DOI is an effective mechanism to treat a pathological
inflammatory disease, we investigated the effects of the highly
selective 5-HT2 receptor agonist (R)-DOI in a mouse model of
allergic asthma. By building upon our earlier in vitro and in
vivo studies, we demonstrate here that inhaled (R)-DOI has
potent anti-inflammatory effects and blocks the development of
allergic asthma in the OVA mouse model. Importantly, we
have already established that the anti-inflammatory effects of
(R)-DOI in vitro and in vivo are mediated through activation
of the serotonin 5-HT2A receptor subtype (33, 53). Here, we tested
two different doses of (R)-DOI. The 1.0-mg/kg dose is in the
range of that used in typical behavioral experiments (41). The
very low dose of 0.01 mg/kg was chosen to test the super potency
of (R)-DOI, predicted by our previous cellular studies (53). Anti-
inflammatory effects of this very low dose were also observed in
our recent in vivo study examining the ability of (R)-DOI to block
the effects of systemic administration of TNF- (33). Because
activation of the 5-HT2A receptor subtype and not the 5-HT2C
receptor subtype was found to be necessary for the anti-inflam-
matory effects of (R)-DOI in our previous studies, we hypothe-
sized that the effects of (R)-DOI against allergic asthma were also
mediated through 5-HT2A receptor activation. Although we were
not able to validate this here, we have confirmed the presence of
5-HT2A receptor mRNA on whole-lung tissue (33). Furthermore,
the expression of 5-HT2A receptors has been reported in airway
smooth muscle cells (2) and alveolar macrophages (30), and
although naïve T cells do not express high levels of the 5-HT2A
receptor, activated T cells do express high levels of 5-HT2A
Fig. 4. Bronchoalveolar lavage fluid (BALF) cellularity is altered in mice
exposed to OVA but not in mice exposed to OVA and treated with (R)-DOI.
BAL cellularities and differentials are expressed as the product of the total
number of cells recovered and the percentages of each cell type derived from
differentials. The total number of cells is nearly double in the OVA-alone-
treated mice compared with naïve (Total). (R)-DOI treatment, before OVA
exposure, reduced the total cellularity back to naïve levels. This difference was
primarily due to a significant reduction in eosinophils (Eos) in the mice treated
with (R)-DOI. No significant differences in the numbers of macrophages
(Macs), lymphocytes (Lymphs), or neutrophils (Neutros) were observed be-
tween treatment groups. *OVA-only vs. Naïve (P 
 0.001) and #OVA-only
vs. (R)-DOI  OVA (P 
 0.01); n  5–6 animals/treatment group; error bars
represent  SE; 2-way ANOVA with Bonferroni post hoc test. Total cells
(10e5)  y-axis value multiplied by 1 x 105.
Fig. 3. Inhaled (R)-DOI reduces mucus cell hyperplasia and mucus production
in the airway. The fraction of airway cells containing mucus, as determined by
PAS staining (see Fig. 2), was determined for 2 doses of (R)-DOI in 2 separate
experiments. Results are presented as normalized to OVA  100%. Naïve
airways did not contain PAS-positive cells, and OVA sensitization dramati-
cally increases mucus production (OVA). A: the number of airway cells
containing mucus is reduced significantly by administration of aerosolized
(R)-DOI before OVA challenge (0.01 mg/kg DOI  OVA). B: the number of
airway cells containing mucus is nearly abolished by inhaled (R)-DOI treat-
ment at 1.0 mg/kg (DOI  OVA). *P 
 0.0001 vs. Naïve, #P 
 0.0001 vs.
OVA, and P̂ 
 0.001 vs. Naïve error bars represent  SE; ANOVA with
Tukey post hoc test. All airways/section, which included both lungs, were
scored by an unbiased observer for each of 3 animals/treatment (n  3).
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receptor mRNA (23). We suggest that the site of therapeutic
action is directly on the pulmonary tissues, including resident-
activated T cell populations and/or innate-immune cells.
The major components of allergic asthma in humans include
AHR, pulmonary inflammation, and mucus hyperproduction
(7). In addition, eosinophils, which release cytotoxic mediators
and leukotrienes, are recruited in large numbers to the lungs of
asthmatic individuals (37). Eosinophil production, chemotaxis,
and survival are controlled by regulated on activation, normal
T cell expressed and secreted (CC chemokine ligand 5), mac-
rophage inflammatory protein 1, eotaxins, IL-5, and GM-CSF
(18, 25, 35, 43, 47). IL-5 and GM-CSF are derived from
activated pulmonary epithelial cells, eosinophils themselves,
and activated T-lymphocytes (1, 27, 50). IL-5 and GM-CSF are
Fig. 5. Total protein and IgE levels are not affected by (R)-DOI (1.0 mg/ml, nose only). A: the total of protein content in the BALF, as measured by bicinchoninic
acid assay, is increased significantly in the OVA-only-treated lungs compared with naïve. (R)-DOI does not alter total BALF protein induced by OVA. B: total
plasma IgE, as measured by ELISA, is increased significantly by OVA treatment. (R)-DOI, administered before OVA challenge, has no effect on total plasma
IgE. C: OVA-specific plasma IgE, as measured by ELISA, is increased significantly by OVA treatment. (R)-DOI, administered before OVA challenge, has no
effect on OVA-specific plasma IgE. ***P 
 0.001 vs. OVA; n.s.  no significance vs. OVA; n  7–17 animals/treatment group; error bars represent  SE;
ANOVA with Tukey post hoc test.
Fig. 6. Inhaled (R)-DOI (1.0 mg/kg) inhibits proinflammatory gene expression in the whole lung. Quantitative RT-PCR measurement of mRNA expression levels
of several inflammatory markers is shown. OVA produces a significant increase in the mRNA levels of Il-4 (A), Il-10 (B), monocyte chemotactic protein-1
(Mcp-1; E), Il-13 (F), Il-5 (G), and granulocyte macrophage colony-stimulating factor (Gm-csf; H) compared with naïve. No significant effect of OVA was
observed on Tnf (C) or Il-6 (D) expression. (R)-DOI produces significant inhibition of the OVA-induced increases in the mRNA expression of Mcp-1, Il-13,
Il-5, and Gm-csf. Although Il-6 levels were not statistically different between naïve and OVA groups, (R)-DOI elicited a significant decrease in Il-6 expression
levels when administered before OVA exposure compared with OVA alone. ***P 
 0.0001, **P 
 0.01, and *P 
 0.05; n.s.  no significance; n  4 animals
for the Naïve group, and n  10 animals for the OVA and DOI  OVA treatment groups; error bars represent  SE; ANOVA with Tukey post hoc test.
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molecules important in the development of asthma and are
increased in serum and BALF of asthmatics in the clinic (12,
44). Significantly, our data show that both genes are suppressed
by administration of (R)-DOI in the OVA mouse model.
The role of eosinophils in asthma is both direct, causing
bronchoconstriction and destruction to airways, and indirect by
provoking degranulation of mast cells and basophils (7). We
demonstrate here that (R)-DOI blocks recruitment of eosino-
phils to the lung, prevents mucus hyperproduction, blocks
AHR, and represses T helper cell 2 (Th2) and innate-immune
cell gene expression (e.g., Il-5 and Mcp-1). We delivered
(R)-DOI directly to the lung using inhalation techniques in
these experiments, and it remains to be determined whether
systemically injected (R)-DOI has the same or similar effects
on the development of asthma. Importantly, effective levels of
(R)-DOI, administered by this route (inhalation), are orders of
magnitude less than those necessary to produce either behav-
ioral intoxication, as indicated by the classical head-twitch
response (9), or airways constriction in mice (10 mg/kg
inhaled; data not shown).
Although the presence of 5-HT2A receptor mRNA has been
demonstrated in pulmonary tissues by our lab and others, the
role of this receptor in the lung has remained largely undefined.
A few reports have suggested that the 5-HT2A receptor medi-
ates AHR in allergic asthma (14, 40, 54). However, these
studies used the antagonist ketanserin, which is nonselective in
rodents for 5-HT2 receptors and also has high affinity for
histamine H1 and -adrenergic receptors, to block the effects
of serotonin. This makes it difficult to interpret results using
ketanserin. In any case, these reports indicated that serotonin
activation of 5-HT2A receptors contributes to AHR rather than
preventing it. Serotonin itself has been implicated in airways
inflammation in allergic asthma by acting as a critical factor to
recruit inflammatory cells and prime Th2 responses by activa-
tion of bone marrow-derived dendritic cells, although the
receptor(s) mediating these effects remain unknown (13). Con-
versely, blockade of serotonin receptors with a nonselective
antagonist for multiple subtypes has demonstrated antiasthma
effects in the OVA model (24, 40). Why then, if serotonin
appears to have a proinflammatory effect in the lung, does
activation of 5-HT2 receptors with (R)-DOI have an anti-
inflammatory effect? One possibility is that selective activation
of 5-HT2 receptors with (R)-DOI avoids activation of other
serotonin receptor types responsible for the inflammatory re-
sponse. A more likely explanation is that (R)-DOI, which has
a much higher affinity for the 5-HT2 receptors than serotonin,
is acting as a functionally selective ligand and recruiting
anti-inflammatory effector pathways that serotonin itself does
not (26, 31). Significantly, (R)-DOI has already been shown to
activate different signaling pathways than serotonin at the
5-HT2A receptor in vivo (38, 39).
It is unlikely that the therapeutic mechanistic site of action of
(R)-DOI is on the B cell or the antigen-presenting cell, as
(R)-DOI has no effect on OVA-induced Il-4 gene expression.
Recent reports indicate that IgE-dependent mast cell activation
is involved in the development of AHR (28). The fact that
(R)-DOI has no measureable effect on humoral IgE production,
yet prevents AHR, suggests (R)-DOI is acting on activated
rather than naïve T cells to block AHR through nonmast
cell-dependent mechanisms. Because (R)-DOI blocks Mcp-1
and Gm-csf mRNA production, the therapeutic target may also
include innate immune cells. There is also the possibility that
(R)-DOI may be acting on the naïve CD4 population; how-
ever, naïve T cells do not express high levels of 5-HT2A
receptor mRNA until activated. Our data demonstrate that
(R)-DOI treatment significantly inhibits the OVA-induced ex-
pression of Th2-related genes that include Il-13, Il-5, and
Gm-csf in the lung. Interestingly, vascular (or more likely,
epithelial) permeability is not improved with (R)-DOI, as total
protein in the BALF is not reduced compared with OVA alone.
We propose a model, shown in Fig. 7, where the pool of
5-HT2A receptors activated by (R)-DOI that responds with
Fig. 7. A proposed therapeutic mechanism of (R)-DOI.
The presented data show that (R)-DOI has no effect on
Il-4 gene expression, as well as no effect on humoral
IgE production. These data provide evidence that the
therapeutic action of (R)-DOI is not on the B cell, the
antigen-presenting cell (APC), and/or the naïve CD4
population. Importantly, we show that (R)-DOI treat-
ment significantly inhibits expression of T helper cell 2
(Th2)-related genes, including Mcp-1, Il-13, Il-5, and
Gm-csf compared with asthmatic animals. Taken to-
gether, we suggest that (R)-DOI exerts its therapeutic
action in the OVA asthma model by activating anti-
inflammatory signaling pathways through the serotonin
5-hydroxytryptamine 2A receptors on T cells and/or
innate immune cells, leading to a decrease in secretion
of Il-13, resulting in a decrease in mucus production; a
decrease in Il-5 and Gm-csf secretion, leading to a
decrease in eosinophilia recruitment; and a decrease in
Mcp-1 production, leading to a decrease in Th2 polar-
ization. These changes contribute to a general decrease
in both inflammation and AHR.
L196 5-HT2 ACTIVATION PREVENTS ASTHMA
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00138.2013 • www.ajplung.org
Downloaded from journals.physiology.org/journal/ajplung at LSU Louisiana State Univ (130.039.060.163) on September 24, 2021.
anti-inflammatory properties could reside on activated Th2
cells and/or innate immune cells. In this proposed model,
5-HT
2A
receptor activation would lead to reduced IL-5, GM-
CSF, and MCP-1 secretion, in turn, decreasing eosinophil
recruitment, Th2 polarization, and IL-13 production (16, 22,
48, 55). Overall, these effects would combine to reduce in-
flammation and AHR. The precise cellular signaling pathways,
however, remain to be elucidated.
In conclusion, we have identified an important and new
functional role of 5-HT2 receptors in the lung. (R)-DOI acti-
vation of serotonin 5-HT2 receptors potently prevents the
development of a clinically relevant mouse model of allergic
asthma at drug levels far below those necessary to invoke
adverse cardiovascular or behavioral effects. Based on our
previous in vitro and in vivo studies, we predict that it is the
5-HT2A receptor that is the therapeutic target of (R)-DOI in our
model. Our results demonstrate that activation of 5-HT2 recep-
tors differentially regulates Th2 signaling, innate cytokine
responses, and other relevant inflammatory effector pathways
and that selective activation with (R)-DOI, or perhaps other
5-HT2A agonists in its class, represents a novel, small mole-
cule-based therapeutic strategy for the treatment of asthma.
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